MERIDIAN, Idaho, March 18 /PRNewswire-FirstCall/ -- RxElite, Inc. , a developer, manufacturer, and marketer of specialty generic prescription drug products, today announced it will discuss its 2007 year-end financial results in a conference call on Thursday, March 20, 2008, at 11:00 a.m. EDT.
The Company will release its 2007 year-end financial results after the market closes on Wednesday, March 19, 2008. Hosting the call will be RxElite CEO Jonathan Houssian, COO Earl E. Sullivan, and VP of Finance Shannon M. Stith.
Conference Call
To participate in the conference call, callers from the USA and Canada please dial 1(800) 219-6110, all other international calls please dial (303) 262-2130. All callers should dial in five to ten minutes prior to the conference call time.
Audio Stream and Webcast
You may also participate via live audio stream by logging on to http://www.investquest.com/iq/r/rxelite/. A rebroadcast of the audio stream will be available using the same web link for 90 days after the initial broadcast.
About RxElite, Inc.
RxElite, Inc. develops, manufactures and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics and injectable drugs) and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
chbird@segue.biz
CONTACT: Corporate Information, +1-208-288-5550, Toll Free,
+1-800-414-1901, Fax, +1-208-288-1191, or Investor Relations, Craig Bird of
Segue Ventures LLC for RxElite, Inc., +1-215-885-4981, chbird@segue.biz
Web site: http://www.investquest.com/iq/r/rxelite/
